You are here: Industry Insights > Desidustat

News List

Desidustat Shows Efficacy, Safety Treating Hypoxia in Hospitalized COVID-19 Patients americanpharmaceuticalreview
January 29, 2021
Zydus announced it has received positive results from Phase 2(b) studies of Desidustat in COVID-19 patients conducted at Mexico.
Desidustat prevents development of ARDS in Phase II COVID-19 trial europeanpharmaceuticalreview
January 28, 2021
In a Phase IIb trial, hospitalised COVID-19 patients treated with desidustat did not develop acute respiratory distress syndrome (ARDS).
Zydus’ Desidustat efficacious in treating hypoxia in Mexico’s hospitalised COVID-19 patients: Study expresspharma
January 25, 2021
None of the hospitalised patients required mechanical ventilator in the Desidustat arm, while 25 per cent patients on the standard of care arm required mechanical ventilator.
Zydus Cadila gets US FDA nod for drug trials to treat chemotherapy-induced anemia expresspharma
July 24, 2020
Desidustat is a novel drug which is also currently undergoing phase-III trials for treating anemia in chronic kidney disease patients and phase-II studies for management of COVID-19 patients.
Zydus gets nod from COFEPRIS, Mexico to study Desidustat for COVID-19 management expresspharma
July 07, 2020
As a part of the study, 100 mg tablets of Desidustat will be administered for a period of 14 days along with recommended standard care during the trial.
Zydus Cadila announces phase III trial of Desidustat biospectrumasia
April 21, 2019
This Phase III study will be a multicenter (50- 60 sites), randomized, active-controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Darbepoetin